| Identification | Back Directory | [Name]
corydalmine | [CAS]
30413-84-4 | [Synonyms]
Kikemanin
Kikemanine
Schefferine
corydalmine
(-)-Kikemanine
(13aS)-5,8,13,13a-Tetrahydro-2,3,9-trimethoxy-6H-dibenzo[a,g]quinolizin-10-ol
6H-Dibenzo[a,g]quinolizin-10-ol,5,8,13,13a-tetrahydro-2,3,9-trimethoxy-, (13aS)-
(13aS)-2,3,9-Trimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinolin-10-ol | [Molecular Formula]
C20H23NO4 | [MDL Number]
MFCD17214809 | [MOL File]
30413-84-4.mol | [Molecular Weight]
341.4 |
| Chemical Properties | Back Directory | [Melting point ]
177-178℃ | [Boiling point ]
501.2±50.0 °C(Predicted) | [density ]
1.29 | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | [form ]
Powder | [pka]
9.97±0.20(Predicted) |
| Hazard Information | Back Directory | [Uses]
Corydalmine (L-Corydalmine) inhibits spore germination of some plant pathogenic as well as saprophytic fungi[1]. Corydalmine acts as an oral analgesic agent, exhibiting potent analgesic activity[2]. Corydalmine alleviates Vincristine-induced neuropathic pain in mice by inhibiting an NF-κB-dependent CXCL1/CXCR2 signaling pathway[3]. | [in vivo]
Corydalmine (L-Corydalmine) is a potent analgesic agent, in cynomolgus monkey, beagle dog, rat and mouse liver microsomes[2]. | [target]
P450 (e.g. CYP17) | Antifection | [IC 50]
CXCR2 | [References]
[1] S Ameer Basha, et al. Effect of 1-corydalmine, an Alkaloid Isolated From Corydalis Chaerophylla Roots on Spore Germination of Some Fungi. Mycobiology. 2007 Jun;35(2):69-71. DOI:10.4489/MYCO.2007.35.2.069
[2] Xiange Tang, et al. In Vitro Metabolism of L-Corydalmine, a Potent Analgesic Drug, in Human, Cynomolgus Monkey, Beagle Dog, Rat and Mouse Liver Microsomes. J Pharm Biomed Anal. 2016 Sep 5;128:98-105. DOI:10.1016/j.jpba.2016.05.024
[3] Lin Zhou, et al. Levo-corydalmine Alleviates Vincristine-Induced Neuropathic Pain in Mice by Inhibiting an NF-kappa B-dependent CXCL1/CXCR2 Signaling Pathway. Neuropharmacology. 2018 Jun;135:34-47. DOI:10.1016/j.neuropharm.2018.03.004 |
|
|